120 related articles for article (PubMed ID: 21157026)
41. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
[TBL] [Abstract][Full Text] [Related]
42. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
43. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
44. PET studies and cholinergic therapy in Alzheimer's disease.
Nordberg A
Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
[TBL] [Abstract][Full Text] [Related]
45. CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.
Karami A; Eriksdotter M; Kadir A; Almkvist O; Nordberg A; Darreh-Shori T
Front Mol Neurosci; 2019; 12():239. PubMed ID: 31680850
[TBL] [Abstract][Full Text] [Related]
46. Short-term longitudinal evaluation of cerebral blood flow in mild Alzheimer's disease.
Tonini G; Shanks MF; Venneri A
Neurol Sci; 2003 Apr; 24(1):24-30. PubMed ID: 12754653
[TBL] [Abstract][Full Text] [Related]
47. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Penner J; Rupsingh R; Smith M; Wells JL; Borrie MJ; Bartha R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):104-10. PubMed ID: 19833161
[TBL] [Abstract][Full Text] [Related]
48. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease.
Matsuda H; Kitayama N; Ohnishi T; Asada T; Nakano S; Sakamoto S; Imabayashi E; Katoh A
J Nucl Med; 2002 Mar; 43(3):304-11. PubMed ID: 11884488
[TBL] [Abstract][Full Text] [Related]
50. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
51. Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.
Smith GS; Kramer E; Ma Y; Hermann CR; Dhawan V; Chaly T; Eidelberg D
Brain; 2009 Feb; 132(Pt 2):392-401. PubMed ID: 19153152
[TBL] [Abstract][Full Text] [Related]
52. Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
Winblad B; Jelic V; Kershaw P; Amatniek J
Drugs Aging; 2007; 24(1):57-61. PubMed ID: 17233547
[TBL] [Abstract][Full Text] [Related]
53. Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.
Oboshi Y; Kikuchi M; Terada T; Yoshikawa E; Bunai T; Ouchi Y
J Alzheimers Dis; 2016 May; 53(3):817-30. PubMed ID: 27258412
[TBL] [Abstract][Full Text] [Related]
54. Age-related changes in cerebral blood flow and glucose metabolism in conscious rhesus monkeys.
Noda A; Ohba H; Kakiuchi T; Futatsubashi M; Tsukada H; Nishimura S
Brain Res; 2002 May; 936(1-2):76-81. PubMed ID: 11988232
[TBL] [Abstract][Full Text] [Related]
55. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys.
Tsukada H; Kakiuchi T; Fukumoto D; Nishiyama S; Koga K
Brain Res; 2000 Apr; 862(1-2):180-6. PubMed ID: 10799683
[TBL] [Abstract][Full Text] [Related]
56. Comparison of regional cerebral blood flow and glucose metabolism in the normal brain: effect of aging.
Bentourkia M; Bol A; Ivanoiu A; Labar D; Sibomana M; Coppens A; Michel C; Cosnard G; De Volder AG
J Neurol Sci; 2000 Dec; 181(1-2):19-28. PubMed ID: 11099707
[TBL] [Abstract][Full Text] [Related]
57. Blood metabolite markers of cognitive performance and brain function in aging.
Simpson BN; Kim M; Chuang YF; Beason-Held L; Kitner-Triolo M; Kraut M; Lirette ST; Windham BG; Griswold ME; Legido-Quigley C; Thambisetty M
J Cereb Blood Flow Metab; 2016 Jul; 36(7):1212-23. PubMed ID: 26661209
[TBL] [Abstract][Full Text] [Related]
58. Clinical studies in Alzheimer patients with positron emission tomography.
Nordberg A
Behav Brain Res; 1993 Nov; 57(2):215-24. PubMed ID: 7906947
[TBL] [Abstract][Full Text] [Related]
59. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography.
Tune L; Brandt J; Frost JJ; Harris G; Mayberg H; Steele C; Burns A; Sapp J; Folstein MF; Wagner HN
Acta Psychiatr Scand Suppl; 1991; 366():61-5. PubMed ID: 1897377
[TBL] [Abstract][Full Text] [Related]
60. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease.
Minthon L; Nilsson K; Edvinsson L; Wendt PE; Gustafson L
Dementia; 1995; 6(5):245-51. PubMed ID: 8528370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
